link
Bookmarks
Ultrasound Contrast Agents: Sonazoid
Naohisa Kamiyama, PhD
To access 4,300 diagnoses written by the world's leading experts in radiology, please log in or subscribe.Log inSubscribe

KEY FACTS

  • Terminology

    • Clinical Implications

      • Imaging Recommendations

        TERMINOLOGY

        • Definitions

          • Sonazoid
            • US contrast agent manufactured by GE Healthcare AS, Oslo, Norway

        CLINICAL IMPLICATIONS

        • Contrast Agent

          • Pharmacokinetics

            • Storage and Handling

              DOSAGE AND ADMINISTRATION

              • Preparation Instructions

                • Injection Instructions

                  • Manufacturer-Recommended Dosages

                    • Dosage Variations

                      • Technical Pitfalls and Challenges

                        PRECAUTIONS

                        • Adverse Reactions

                          USE IN SPECIFIC POPULATIONS

                          • Pregnancy

                            • Lactation

                              • Elderly Patients

                                Selected References

                                1. Shimazu K et al: Identification of sentinel lymph nodes by contrast-enhanced ultrasonography with Sonazoid in patients with breast cancer: a feasibility study in three hospitals. Cancer Med. 6(8):1915-1922, 2017
                                2. Miyamoto Y et al: Efficacy of sonazoid (perflubutane) for contrast-enhanced ultrasound in the differentiation of focal breast lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 202(4):W400-7, 2014
                                3. Shekhar H et al: Modifying the size distribution of microbubble contrast agents for high-frequency subharmonic imaging. Med Phys. 40(8):082903, 2013
                                4. Correas JM et al: Contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100). Eur Radiol. 21(8):1739-46, 2011
                                5. Moriyasu F et al: Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 193(1):86-95, 2009
                                6. Edey AJ et al: Ultrasound imaging of liver metastases in the delayed parenchymal phase following administration of Sonazoid using a destructive mode technique (Agent Detection Imaging). Clinical Radiology 63:1112-1120, 2008
                                7. Watanabe R et al: Mechanism of hepatic parenchyma-specific contrast of microbubble-based contrast agent for ultrasonography: microscopic studies in rat liver. Invest Radiol. 42(9):643-51, 2007
                                Related Anatomy
                                Loading...
                                Related Differential Diagnoses
                                Loading...
                                References
                                Tables

                                Tables

                                KEY FACTS

                                • Terminology

                                  • Clinical Implications

                                    • Imaging Recommendations

                                      TERMINOLOGY

                                      • Definitions

                                        • Sonazoid
                                          • US contrast agent manufactured by GE Healthcare AS, Oslo, Norway

                                      CLINICAL IMPLICATIONS

                                      • Contrast Agent

                                        • Pharmacokinetics

                                          • Storage and Handling

                                            DOSAGE AND ADMINISTRATION

                                            • Preparation Instructions

                                              • Injection Instructions

                                                • Manufacturer-Recommended Dosages

                                                  • Dosage Variations

                                                    • Technical Pitfalls and Challenges

                                                      PRECAUTIONS

                                                      • Adverse Reactions

                                                        USE IN SPECIFIC POPULATIONS

                                                        • Pregnancy

                                                          • Lactation

                                                            • Elderly Patients

                                                              Selected References

                                                              1. Shimazu K et al: Identification of sentinel lymph nodes by contrast-enhanced ultrasonography with Sonazoid in patients with breast cancer: a feasibility study in three hospitals. Cancer Med. 6(8):1915-1922, 2017
                                                              2. Miyamoto Y et al: Efficacy of sonazoid (perflubutane) for contrast-enhanced ultrasound in the differentiation of focal breast lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 202(4):W400-7, 2014
                                                              3. Shekhar H et al: Modifying the size distribution of microbubble contrast agents for high-frequency subharmonic imaging. Med Phys. 40(8):082903, 2013
                                                              4. Correas JM et al: Contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100). Eur Radiol. 21(8):1739-46, 2011
                                                              5. Moriyasu F et al: Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 193(1):86-95, 2009
                                                              6. Edey AJ et al: Ultrasound imaging of liver metastases in the delayed parenchymal phase following administration of Sonazoid using a destructive mode technique (Agent Detection Imaging). Clinical Radiology 63:1112-1120, 2008
                                                              7. Watanabe R et al: Mechanism of hepatic parenchyma-specific contrast of microbubble-based contrast agent for ultrasonography: microscopic studies in rat liver. Invest Radiol. 42(9):643-51, 2007